论文部分内容阅读
目的探究胰腺癌患者中MIC-1在临床检查血清学诊断中的临床效价。方法选取某院2009年1月～2011年1月行酶联免疫方法对胰腺癌30例(观察组)、胰腺良性病变30例(对照一组)及正常人30例(对照二组)血清MIC-1、CA199水平比较分析。结果观察组(胰腺癌患者)对比对照一组(胰腺良性肿瘤)、对照二组(正常人群组),观察组MIC-1检查结果明显高于其余两组,差异行统计学分析,P均小于0.01,差异有统计学意义。观察组30例患者中,MIC-1检查阳性28例,占93.33%。CA199检查阳性21例,占70%。结论在胰腺癌患者早期诊断、转移中MIC-1检查可发挥较大临床效价。
Objective To investigate the clinical titer of MIC-1 in serological diagnosis of pancreatic cancer patients. Methods From January 2009 to January 2011 in a hospital, 30 cases of pancreatic cancer (observation group), 30 cases of benign pancreatic lesions (control group) and 30 normal subjects (control group 2) serum MIC -1, CA199 level comparative analysis. Results In the observation group (pancreatic cancer patients), the control group (benign pancreatic tumor) and the control group (normal group), the MIC-1 test results of the observation group were significantly higher than the other two groups, statistical analysis of difference, P Less than 0.01, the difference was statistically significant. In the observation group of 30 patients, MIC-1 was positive in 28 cases (93.33%). CA199 positive in 21 cases, accounting for 70%. Conclusions In the early diagnosis and metastasis of pancreatic cancer, the MIC-1 test can exert a great clinical value.